Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance

ISBN-13: 9781461476535 / Angielski / Twarda / 2013 / 202 str.

Benjamin Bonavida

Opis

​​​​The traditional approaches to treat various cancers include chemotherapy, radiation and/or hormonal therapy. While these therapies continue to be effective in large part, they are not selective and highly toxic. There have been encouraging results in alternative therapeutic approach called antibody-mediated anti-cancer therapy, which is less toxic, more selective, and can also reverse drug/radiation resistance. Monoclonal antibodies or mAbs can be used to destroy malignant tumor cells and prevent tumor growth by blocking specific cell receptors. mAbs can bind only to cancer cell-specific antigens and induce an immunological response against the target cancer cell. The book covers the common and unique features of mAbs agains various cancer, gives the latest developments on the molecular, biochemical and genetic mechanisms of resistance by various mAbs, as well as discuss novel mAbs to overcome resistance.

Spis treści

​Part I. Immunotherapy with monoclonal antibodies (mAbs) against various cancers 1.Introduction and generation of chimeric and humanized mAbs 2. mAbs targeted against cancer cells and antibodies targeted against the tumor microenvironment 3. Antibodies directed against different major cancers: Effects when used alone or in combination with drugs 4. Mechanisms of antibodies-mediated responses, in vitro and in vivo Part II. Development of resistance to mAbs 5. Molecular Pathways 6. Molecular Signatures 7. Identification of resistance targets for intervention Part III. Agents that can sensitize resistant tumor cells to mAbs 8. Various chemicals that can sensitize resitant tumor cells 9. Other mAbs 10. Proteasome inhibitors Part IV. Novel mAbs to overcome resistance 11. Divalent mAbs 12. Antibodies coupled to chemical inhibitors 13. Antibodies coupled to cytokines 14. Nanoparticles with mAbs ​

O autorze

Dr. Benjamin Bonavida is a professor at UCLA's David Geffen School of Medicine for the Department of Microbiology, Immunology, & Molecular Genetics. His other appointments include being a member of the Department of Defense Congressionally Directed Medical Research Program, Member of the National Cancer Institute's SPORE Program, member of the International Scientific Advisory Board of the Israel Cancer Research Foundation, to name a few. He's currently a scientific reviewer for several journals and a member of editorial boards including Journal of Clinical Immunology, International Journal of Oncology, and Cancer Biotherapy & Radiopharmaceuticals. In his career, he's published over 450 papers and reviews, and he's also edited two books with Springer in the past. For more information, please see the CV attached herewith.

Blurb

The current application of antibody-meditated targeted therapy against cancer has resulted in significant objective clinical responses, prolongation of survival and even cures. More than 20 mAbs have been approved for human use targeting a range of different cancers. However, a major drawback of mAb therapeutics is that a subset of patients does not initially respond and another initially responding subset develops resistance to further treatments. At the present time, there are no effective therapies for these subsets of cancer patients. The analyses of underlying mechanisms responsible for resistance are necessary to develop and generate new targeted therapies that overcome the resistance.

Resistance to Immunotherapeutic Antibodies in Cancer: Strategies to Overcome Resistance is a timely volume that deals with various mechanisms of resistance to anti-cancer mAbs therapeutics as well as it deals with novel approaches to overcome resistance. The reviews in this volume are written by highly qualified, established and experienced leaders in the field of resistance to anti-cancer mAbs.